Sign In
Buy TPST
$1.27
-0.0400 (-3.05%)
At Close: Jun 03, 2026
Tempest Therapeutics' stock jumps 1,900% as liver-cancer treatment shows promise
12:29pm, Wednesday, 11'th Oct 2023
Shares of Tempest Therapeutics Inc. TPST, +1942.52% soared more than 1,900% on Wednesday after the company released study results for its investigational cancer treatment TPST-1120 in patients with li
Why Is Tempest Therapeutics (TPST) Stock Up 325% Today?
07:41am, Wednesday, 11'th Oct 2023
Tempest Therapeutics (NASDAQ: TPST ) stock is taking off on Wednesday as the clinical-stage oncology company prepares to release new study results. According to a press release from the company, it i
Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
04:05pm, Tuesday, 10'th Oct 2023
Webcasted Conference Call on Wednesday, October 11, 2023 at 8:30 a.m. ET Webcasted Conference Call on Wednesday, October 11, 2023 at 8:30 a.m. ET
All You Need to Know About Tempest Therapeutics, Inc. (TPST) Rating Upgrade to Buy
05:42pm, Tuesday, 15'th Aug 2023
Tempest Therapeutics, Inc. (TPST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Tempest to Present at the Jefferies Global Healthcare Conference
04:05pm, Wednesday, 31'st May 2023
BRISBANE, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and i
Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers
05:00pm, Thursday, 25'th May 2023
• Data show tumor shrinkage and prolonged disease control in both monotherapy and in combination with pembrolizumab • Oral, once-daily cancer treatment well tolerated with a manageable safety prof
Tempest Therapeutics, Inc. (TPST) Upgraded to Buy: What Does It Mean for the Stock?
01:42pm, Monday, 01'st May 2023
Tempest Therapeutics, Inc. (TPST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
04:58pm, Thursday, 27'th Apr 2023
BRISBANE, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and
Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting
04:30pm, Tuesday, 14'th Mar 2023
BRISBANE, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and
Tempest to Present at the Piper Sandler 34th Annual Healthcare Conference
04:05pm, Tuesday, 22'nd Nov 2022
SOUTH SAN FRANCISCO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company focused on developing first-in-class therapeutics that combi
Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit
08:00am, Thursday, 06'th Oct 2022
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both ta
Tempest to Present at the Jefferies Healthcare Conference
04:05pm, Monday, 06'th Jun 2022
SOUTH SAN FRANCISCO, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both ta
3 Must Watch Penny Stocks For Your Small-Caps List
05:52pm, Wednesday, 27'th Apr 2022
These must watch penny stocks are worth giving a look The post 3 Must Watch Penny Stocks For Your Small-Caps List appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com
Why Tempest Therapeutics Shares Are Rising
12:09pm, Wednesday, 27'th Apr 2022
Tempest Therapeutics Inc (NASDAQ: TPST) shares are trading higher by 29.24% at $3.05 after the company announced $15 million of private placement financing. The $15 million private investment in pub
Tempest to Present at the 32nd Annual Oppenheimer Healthcare Conference
08:00am, Thursday, 10'th Mar 2022
SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both t
